Amgen

Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Biopharma Reporter
obesity
weight loss
Novo Nordisk
Eli Lilly
Pfizer
Amgen
Flag link:
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
Motley Fool
FTC
M&A
Amgen
Horizon Therapeutics
Pfizer
Seagen
Flag link:
Bayer, Amgen looked at Iveric before agreeing to Astellas sale
Bayer, Amgen looked at Iveric before agreeing to Astellas sale
Seeking Alpha
Astellas
Iveric Bio
Bayer
Amgen
M&A
Flag link:
Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Yahoo/Reuters
JNJ
Amgen
patents
Stelara
biosimilars
legal
Flag link:
Horizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block it
Horizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block it
CNBC
Horizon Therapeutics
M&A
Amgen
FTC
Flag link:
Supreme Court rules against Amgen bid to revive cholesterol drug patents
Supreme Court rules against Amgen bid to revive cholesterol drug patents
KFGO/Reuters
Supreme Court
Amgen
Sanofi
Regeneron
patents
Repatha
legal
Flag link:
Few signs of gout pipeline flaring up
Few signs of gout pipeline flaring up
EP Vantage
gout
Selecta Biosciences
Sobi
SEL-212
3SBio
Amgen
Arthrosi Therapeutics
Atom Bioscience
Dyve Biosciences
Hinova Pharmaceuticals
Horizon Therapeutics
InventisBio
Jiangsu Hengrui Pharmaceuticals
JW Group
LG Chem
Olatec Therapeutics
Shanton Bioscience
Flag link:
Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal
Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal
Medical Marketing and Media
Amgen
Horizon Therapeutics
FTC
Regeneron
antitrust
M&A
Leonard Schleifer
Flag link:
Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say
Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say
Fierce Pharma
FTC
M&A
Amgen
Horizon Therapeutics
Pfizer
Seagen
antitrust
Flag link:
Heightened US antitrust fears rattle biopharma
Heightened US antitrust fears rattle biopharma
EP Vantage
M&A
antitrust
Amgen
Astellas
Bellus Health
Globus Medical
GSK
Horizon Therapeutics
Merck
NuVasive
Pfizer
Prometheus Biosciences
Seagen
Flag link:
Amgen ‘Remains Committed’ to $27.8B Horizon Acquisition After FTC Challenge
Amgen ‘Remains Committed’ to $27.8B Horizon Acquisition After FTC Challenge
BioSpace
Amgen
Horizon Therapeutics
M&A
FTC
Flag link:
FTC sues to block Amgen’s $27.8B deal for Horizon Therapeutics
FTC sues to block Amgen’s $27.8B deal for Horizon Therapeutics
Medical Marketing and Media
Amgen
Horizon Therapeutics
FTC
M&A
Flag link:
Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear
Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear
Fierce Pharma
Mirati Therapeutics
Krazati
Amgen
Lumakras
lung cancer
Flag link:
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
Amgen invests in TScan’s TargetScan platform for Crohn’s Disease breakthroughs
Amgen invests in TScan’s TargetScan platform for Crohn’s Disease breakthroughs
Medical Marketing and Media
Amgen
TScan
TargetScan
Crohn's Disease
Flag link:
Amgen, Entera ax $270M oral biologic pact 'out of mutual convenience'
Amgen, Entera ax $270M oral biologic pact 'out of mutual convenience'
Fierce Biotech
Amgen
Entera Bio
Flag link:
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Yahoo/Benzinga
Amgen
Sandoz
legal
Prolia
Xgeva
patents
denosumab
Flag link:
As Amgen's revenues slide, so too do sales at its big buyout target Horizon
As Amgen's revenues slide, so too do sales at its big buyout target Horizon
Fierce Pharma
Amgen
earnings
Horizon Therapeutics
Flag link:
Chronic hives: Four major clinical trials to watch in 2023
Chronic hives: Four major clinical trials to watch in 2023
Clinical Trials Arena
chronic hives
chronic urticaria
clinical trials
Sanofi
Regeneron
dupilumab
Amgen
tezepelumab
Allakos
lirentelimab
Celldex Therapeutics
barzolvolimab
Flag link:

Pages